Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Automation will Represent the Next Big Step for Biobanks, Says Frost & Sullivan

Published: Monday, January 07, 2013
Last Updated: Monday, January 07, 2013
Bookmark and Share
Exponential growth in sample volumes pushes biobanks toward automation.

Every year, nearly 100 million samples are added to biobanks worldwide. Over 1500 bio repositories exist today and efforts are underway to automate the various sample handling and compound storage processes involved in biobanking.

The increased focus on preservation of sample integrity and biobanking efficiency is creating considerable growth opportunities for automated solutions.

New analysis from Frost & Sullivan (http://www.healthcare.frost.com), Global Biobanking Automation Market, finds that the market earned revenues of $818 million in 2011 and estimates this to reach $1.4 billion in 2018.

The research covers automated liquid handling systems and robotics, automated compound storage and sample management systems, laboratory information management systems (LIMS) and consumables.

“New disease-based biobank projects in Europe and the United States, that focus on finding a cure for diseases, offer tremendous potential for automation,” notes Senior Research Analyst Divyaa Ravishankar. “As patient population samples surge, automated storage units have now been developed that improve biobanks’ capacity to cater to a larger number of samples.”

Automating certain procedures within the biobanking workflow offers biorepositories with vital technical and cost benefits. The prospects for greater automation within biobanks are being promoted by LIMS.

“Advances in LIMS have led to newer models such as virtual biobanks and centralized databank models which provide a platform for universities, biotechnology and pharmaceutical firms to collaborate,” remarks Ravishankar. “This will facilitate the availability of information to any researcher at any point of the R&D process.”

A key technological challenge at present stems from the fact that no two biobanks operate in a similar way. As a result, there can be no comparison of research results obtained from two different biobanks.

The quality, extent and type of clinical information collected with the specimens also vary from repository to repository.

A diverse and technologically sound portfolio will be necessary to support the greater use of automation in biomarker applications. Strategic alliances and partnerships with technology leaders, academic biobanks and small regional participants will further aid market development.

“Most regional participants have modular systems and a well-established distribution chain,” concluded Ravishankar. “Global participants, providing multi-component systems, could form strategic partnerships with these companies to leverage their distribution chain.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Increased Public Private Partnerships to Drive Cutting Edge Innovation and Business Growth
Faced with increasing challenges such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself.
Thursday, October 08, 2015
Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.
Thursday, June 19, 2014
New Applications in Drug Discovery Platforms to Fuel Advance of Stem Cells
Ethical, clinical and commercial issues to be navigated before full potential of stem cell therapies can be unleashed.
Wednesday, December 12, 2012
Frost & Sullivan gives an overview of the Global Automated Biobanking market
Robotics to aid and drive long term vision of truly personalised medicine
Friday, May 11, 2012
Scientific News
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Edited Stem Cells Offer Hope of Precision Therapy for Blindness
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Newfound Strength in Regenerative Medicine
A promising new approach uses direct mechanical stimulation to repair severely damaged skeletal muscles.
Mapping out Cell Conversion
Researchers develop algorithm that takes the field of cell reprogramming forward.
Donor's Genotype Controls the Differentiation of IPS Cells
Pluripotent stem cells derived from different cell types are equally susceptible to reprogramming, indicates a recent study by the University of Helsinki and the National Institute for Health and Welfare, Finland. However, the genotype of the donor strongly influences the differentiation of the stem cell.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!